AstraZeneca, Oxford to produce Omicron-targeted vaccine
AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine. The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford. A lab-study last week found that AstraZeneca's antibody cocktail Evusheld retained neutralising activity against the Omicron variant. Vaccine makers Pfizer/BioNTech and Moderna also previously said they were working on Omicron- specific Covid-19 vaccines.
Comments